Drosophila melanogaster
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA90461 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Analysis of ZM behavioral differentiation. 3-5 days nonvirgin female fly heads.
2008-06-11 | E-GEOD-1846 | biostudies-arrayexpress
Project description:Analysis of ZM behavioral differentiation. 3-5 days nonvirgin female fly heads. Keywords: other
2005-12-04 | GSE1846 | GEO
Project description:Deterministic Genetic Barcoding for Multiplexed Behavioral and Single Cell Transcriptomic Studies
| PRJNA912199 | ENA
Project description:The foraging gene in Drosophila mediates metabolic as well as behavioral plasticity
| PRJNA111413 | ENA
Project description:Comparative analysis of gene expression changes during differentiation in the Drosophila wing
| PRJNA151721 | ENA
Project description:Osteoporosis affects millions of people worldwide, and current medications like bisphosphonates and denosumab are not effective enough in reversing bone loss. Moreover, these treatments have drawbacks, including jaw osteonecrosis and skin eczema. Hence, there is an urgent need for new drugs to treat osteoporosis. Drug library screening was performed by alkaline phosphatase (ALP) staining in osteoblasts to identify potential candidates for osteoporosis. qPCR, Western blot, ALP staining, alizarin red staining, and TRAP staining were conducted to assess the impact of ZM-306416 (ZM) on osteoblast and osteoclast differentiation in vitro. Additionally, RNA sequencing and pathway analysis were carried out to explore molecular mechanisms. Micro-CT scan and immunostaining were used to determine bone phenotypes in vivo. Drug library screening demonstrated that ZM enhances ALP activity in osteoblasts, indicating its potential as a pro-osteogenic agent. ZM exerts dual effects by promoting osteoblast differentiation through the Wnt/β-catenin signaling pathway and simultaneously inhibiting osteoclast differentiation by the NF-κB and MAPK signaling pathways. In an OVX mouse model, ZM effectively prevents bone loss by stimulating osteoblast formation and inhibiting osteoclast development. Our study revealed that ZM has a dual anti-osteoporosis effect by promoting osteoblastogenesis and inhibiting osteoclastogenesis, mediated via activation of Wnt/β-catenin signaling and suppression of NF-κB/MAPK cascades. These findings suggest that ZM could be a promising therapeutic strategy for alleviating osteoporosis.
2026-03-11 | GSE307904 | GEO
Project description:Osteoporosis affects millions of people worldwide, and current medications like bisphosphonates and denosumab are not effective enough in reversing bone loss. Moreover, these treatments have drawbacks, including jaw osteonecrosis and skin eczema. Hence, there is an urgent need for new drugs to treat osteoporosis. Drug library screening was performed by alkaline phosphatase (ALP) staining in osteoblasts to identify potential candidates for osteoporosis. qPCR, Western blot, ALP staining, alizarin red staining, and TRAP staining were conducted to assess the impact of ZM-306416 (ZM) on osteoblast and osteoclast differentiation in vitro. Additionally, RNA sequencing and pathway analysis were carried out to explore molecular mechanisms. Micro-CT scan and immunostaining were used to determine bone phenotypes in vivo. Drug library screening demonstrated that ZM enhances ALP activity in osteoblasts, indicating its potential as a pro-osteogenic agent. ZM exerts dual effects by promoting osteoblast differentiation through the Wnt/β-catenin signaling pathway and simultaneously inhibiting osteoclast differentiation by the NF-κB and MAPK signaling pathways. In an OVX mouse model, ZM effectively prevents bone loss by stimulating osteoblast formation and inhibiting osteoclast development. Our study revealed that ZM has a dual anti-osteoporosis effect by promoting osteoblastogenesis and inhibiting osteoclastogenesis, mediated via activation of Wnt/β-catenin signaling and suppression of NF-κB/MAPK cascades. These findings suggest that ZM could be a promising therapeutic strategy for alleviating osteoporosis.
2026-03-11 | GSE307058 | GEO
Project description:Environmental and simulation facility conditions can modulate a behavioral-driven altered gravity response of Drosophila imagoes transcriptome
| PRJNA154237 | ENA
Project description:Social isolation induced transcriptional and behavioral response
| PRJNA481582 | ENA